(l)
a specification of the primary end-points and the secondary end-points, if any, to be measured during the clinical trial;
← anx_I__cpt_4__point_17__point_k__text_1 · All articles · anx_I__cpt_4__point_17__point_l__text_1 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.